Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 8;17(4):e0266852.
doi: 10.1371/journal.pone.0266852. eCollection 2022.

Does a humoral correlate of protection exist for SARS-CoV-2? A systematic review

Julie Perry  1   2 , Selma Osman  1 , James Wright  1 , Melissa Richard-Greenblatt  1 , Sarah A Buchan  1   3   4 , Manish Sadarangani  5   6 , Shelly Bolotin  1   3   4   7
Affiliations

Does a humoral correlate of protection exist for SARS-CoV-2? A systematic review

Julie Perry et al. PLoS One. .

Abstract

Background: A correlate of protection (CoP) is an immunological marker associated with protection against infection. Despite an urgent need, a CoP for SARS-CoV-2 is currently undefined.

Objectives: Our objective was to review the evidence for a humoral correlate of protection for SARS-CoV-2, including variants of concern.

Methods: We searched OVID MEDLINE, EMBASE, Global Health, Biosis Previews and Scopus to January 4, 2022 and pre-prints (using NIH iSearch COVID-19 portfolio) to December 31, 2021, for studies describing SARS-CoV-2 re-infection or breakthrough infection with associated antibody measures. Two reviewers independently extracted study data and performed quality assessment.

Results: Twenty-five studies were included in our systematic review. Two studies examined the correlation of antibody levels to VE, and reported values from 48.5% to 94.2%. Similarly, several studies found an inverse relationship between antibody levels and infection incidence, risk, or viral load, suggesting that both humoral immunity and other immune components contribute to protection. However, individual level data suggest infection can still occur in the presence of high levels of antibodies. Two studies estimated a quantitative CoP: for Ancestral SARS-CoV-2, these included 154 (95% confidence interval (CI) 42, 559) anti-S binding antibody units/mL (BAU/mL), and 28.6% (95% CI 19.2, 29.2%) of the mean convalescent antibody level following infection. One study reported a CoP for the Alpha (B.1.1.7) variant of concern of 171 (95% CI 57, 519) BAU/mL. No studies have yet reported an Omicron-specific CoP.

Conclusions: Our review suggests that a SARS-CoV-2 CoP is likely relative, where higher antibody levels decrease the risk of infection, but do not eliminate it completely. More work is urgently needed in this area to establish a SARS-CoV-2 CoP and guide policy as the pandemic continues.

PubMed Disclaimer

Conflict of interest statement

The other authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. PRISMA diagram.
See this image and copyright information in PMC

References

    1. Milne G, Hames T, Scotton C, Gent N, Johnsen A, Anderson RM, et al.. Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity? Lancet Respir Med. 2021;9(12):1450–66. doi: 10.1016/S2213-2600(21)00407-0 - DOI - PMC - PubMed
    1. Thornburg NJ. Adaptive immunity and SARS-CoV-2 2021 [https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-09-22/0....
    1. Plotkin SA, Orenstein W., Offit P. A, Edwards K.M. Plotkin’s Vaccines, 7th Edition: Elsevier; 2018.
    1. Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis. 2008;47(3):401–9. doi: 10.1086/589862 - DOI - PubMed
    1. Krammer F. A correlate of protection for SARS-CoV-2 vaccines is urgently needed. Nat Med. 2021;27(7):1147–8. doi: 10.1038/s41591-021-01432-4 - DOI - PubMed

Publication types

Substances

Supplementary concepts